Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable semaglutide, the active ingredient in weight loss juggernauts Wegovy and ...
The other day I went to see a plastic surgeon who just happens to be Beverly Hills' best-kept secret. You won't find him on ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...
The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...
Ozempic and its contemporaries are the new craze. But would you believe it when we say that these weight-loss drugs would be ...
On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments continue to improve, federal regulators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results